(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology...
Stats | |
---|---|
今日成交量 | 186 170 |
平均成交量 | 517 917 |
市值 | 687 914 |
EPS | $0 ( 2024-03-08 ) |
下一个收益日期 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0.0140 (0.94%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-01 | Benjamin Laura | Buy | 0 | |
2023-08-01 | Vazzano Joseph Walter | Buy | 0 | |
2021-12-20 | Carchedi Steve | Sell | 70 477 | Stock Options |
2021-12-20 | Carchedi Steve | Sell | 156 025 | Stock Options |
2021-12-20 | Carchedi Steve | Sell | 252 555 | Stock Options |
INSIDER POWER |
---|
0.00 |
Last 5 transactions |
Buy: 0 | Sell: 505 299 |
音量 相关性
Allarity Therapeutics, 相关性 - 货币/商品
Allarity Therapeutics, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-37 000.00 (0.00 %) |
EPS: | $-119.56 |
FY | 2023 |
营收: | $0 |
毛利润: | $-37 000.00 (0.00 %) |
EPS: | $-119.56 |
FY | 2022 |
营收: | $0 |
毛利润: | $-120 000 (0.00 %) |
EPS: | $-2 359.71 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.630 |
Financial Reports:
No articles found.
Allarity Therapeutics,
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。